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Parallel trade is one of the most distinctive benefits of the European single market. In a 
simplified way, parallel trade is legal importing of drug from one country where it is 
legally marketed into a second country where the marketing authorization holder also 
markets that product, but without the consent of the marketing authorization holder. Price 
regulation of medical products makes parallel trade of drugs questionable. Final price for 
customer is not result of an independent decision of pharmaceutical company but it is 
given by relevant authority often regarding the spending power of citizens. Wholesalers are 
taking advantage of these price differences when they are buying cheap drugs in low-price 
countries and selling them with profit in countries where drug price are higher. In theory 
this practice should deliver significant saving for patient and national healthcare insurance 
system in destination countries due to lower price of parallel traded drugs. However many 
studies show minimum impact on drug price in these countries since wholesalers retain 
great part of the financial benefits. On the other hand, negatives of parallel trade are 
evident. Drug shortage in low-price markets is characteristic side effect. Less evident 
issues is represented by significant financial loss for pharmaceutical companies which 
carry major part of new drugs R&D cost.         
 This thesis offers overview of legal aspects of a parallel trade in drugs within the 
European union. First part of thesis includes detailed definition of term parallel trade and 
introduction into relevant legislation. The second and third parts describe ways how 
pharmaceutical companies and member states are facing up to problems caused by parallel 
trade.  
 
 
 
 
 
 
